SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2012

			Three Months Ended March 31

			2012			2011
Revenues:
	U.S. Dermatology⁽¹⁾		$	292,217		$	154,191
	U.S. Neurology and Other			187,708			208,115
	Canada and Australia⁽²⁾			132,569			70,244
	Emerging Markets⁽³⁾			243,609			132,476

		Total revenues		856,103			565,026

Segment profit (loss):
	U.S. Dermatology⁽⁴⁾			88,026			34,576
	U.S. Neurology and Other			52,558			99,741
	Canada and Australia⁽⁵⁾			14,917			20,922
	Emerging Markets⁽⁶⁾			23,189			(559	)

		Total segment profit		178,690			154,680

Corporate⁽⁷⁾				(34,358	)		(58,105	)
Restructuring, integration and other costs				(62,337	)		(17,539	)
Acquired IPR&D				—			(2,000	)
Acquisition-related costs				(7,505	)		(1,507	)
Legal settlements				(3,155	)		(400	)
Acquisition-related contingent consideration				(9,839	)		(386	)

Operating income				61,496			74,743
Interest income				1,123			803
Interest expense				(102,025	)		(68,751	)
Loss on extinguishment of debt				(133	)		(8,262	)
Foreign exchange and other				24,299			2,807
Gain on investments, net				2,059			1,769

(Loss) income before recovery of income taxes			$	(13,181	)	$	3,109

(1): U.S. Dermatology segment revenues in the three-month period ended March 31, 2012 reflect incremental revenues from Dermik, Ortho Dermatologics and Elidel®/Xerese® products and services of $96.0 million, in the aggregate.
(2): Canada and Australia segment revenues in the three-month period ended March 31, 2012 reflect incremental revenues from iNova, Dermik and Afexa products and services of $50.3 million, in the aggregate.
(3): Emerging Markets segment revenues in the three-month period ended March 31, 2012 reflect revenues from PharmaSwiss, Sanitas, iNova, Probiotica, Dermik and Gerot Lannach products and services of $128.9 million, in the aggregate. Emerging Markets segment revenues in the three-month period ended March 31, 2011 reflect revenues from PharmaSwiss products and services of $16.2 million.
(4): U.S. Dermatology segment profit in the three-month period ended March 31, 2012 reflects the addition of Dermik operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $5.7 million and $10.4 million, respectively. U.S. Dermatology segment profit in the three-month period ended March 31, 2012 also reflects the addition of Ortho Dermatologics operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $3.3 million and $9.8 million, respectively.
(5): Canada and Australia segment profit in the three-month period ended March 31, 2012 reflects the addition of Afexa operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $2.4 million and $1.7 million, respectively. Canada and Australia segment profit in the three-month period ended March 31, 2012 also reflects the addition of iNova operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $11.1 million and $8.3 million, respectively. In addition, Canada and Australia segment profit in the three-month period ended March 31, 2012 reflects the addition of Dermik operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $10.0 million and $2.4 million, respectively.
(6): Emerging Markets segment profit in the three-month periods ended March 31, 2012 and 2011 reflects the addition of PharmaSwiss operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to identifiable intangible assets of $7.6 million and the impact of acquisition accounting adjustments related to the fair value adjustments to inventory and identifiable intangible assets of $5.1 million, respectively. Emerging Markets segment profit also reflects the addition of Sanitas and iNova operations, including the impact of acquisition accounting adjustments related to the fair value adjustments to identifiable intangible assets of $7.6 million and $6.3 million, respectively, in the three-month period ended March 31, 2012.
(7): Corporate reflects non-restructuring-related share-based compensation expense of $19.2 million and $29.7 million in the three-month periods ended March 31, 2012 and 2011, respectively.

Schedule of total assets by segment

		As of March 31 2012		As of December 31 2011

Assets:
	U.S. Dermatology	$	3,041,252	$	3,077,119
	U.S. Neurology and Other		4,271,010		4,436,463
	Canada and Australia		1,626,030		1,611,999
	Emerging Markets⁽¹⁾		3,879,790		3,349,821

			12,818,082		12,475,402
	Corporate		801,652		666,311

Total assets		$	13,619,734	$	13,141,713

(1): Emerging Markets segment assets as of March 31, 2012 reflect the provisional amounts of identifiable intangible assets and goodwill of Gerot Lannach of $169.3 million and $9.7 million, respectively. Emerging Markets segment assets as of March 31, 2012 also reflect the amounts of identifiable intangible assets and goodwill of Probiotica of $37.9 million and $45.1 million, respectively.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details